Overexpression of MCL-1 provides OCI-Ly1 with resistance toVenetocalx

Abstract

Overexpression of MCL-1 is an antiapoptotic member of the BCL-2 family and has been seen in various human tumors,
correlating with the patient’s poor prognosis. This study tested whether cancers overexpress MCL-1 to gain resistance to
venetoclax. The expression of MCL-1 protein was measured by Western blot. Cell viability after venetoclax and MCL-1
inhibitor AZD5991 was added was measured by MTT. FP-based binding assays measured Venetoclax’s binding affinity
for MCL-1. The result of the study would give insights into venetoclax resistance and the overexpression of MCL-1 in
NHL OCI-Ly1. Future studies should focus on new drugs that can circumvent this resistance if the hypothesis is correct.